EIP
LAB icon

Easterly Investment Partners’s Standard BioTools LAB Stock Holding History

Easterly Investment Partners’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-12,986
Closed -$96K – 140
2020
Q3 		$96K Sell
12,986
-97,123
-88% -$670K ﹤0.01% 95
2020
Q2 		$442K Sell
110,109
-3,573,631
-97% -$12.4M 0.02% 57
2020
Q1 		$9.36M Sell
3,683,740
-699,907
-16% -$2.3M 0.41% 38
2019
Q4 		$15.3M Sell
4,383,647
-634,557
-13% -$2.23M 0.43% 41
2019
Q3 		$23.2M Sell
5,018,204
-2,876,999
-36% -$22.7M 0.65% 33
2019
Q2 		$97.3M Sell
7,895,203
-1,431,907
-15% -$18.2M 2.44% 21
2019
Q1 		$124M Buy
+9,327,110
New +$98.3M 2.99% 14

Other funds holding LAB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AI
Atom Investors Austin, Texas $1.4B AUM 23.77% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACM
Asymmetry Capital Management San Francisco, California $188M AUM 44.72% 1-Year Est. Return

Easterly Investment Partners's LAB Position: Q4 2020 in Review

Easterly Investment Partners sold out of Standard BioTools (LAB) in Q4 2020, closing a stake of 12,986 shares — an estimated $96K sold.

Easterly Investment Partners first reported a position in LAB in Q1 2019 and held it in 7 quarters. The position peaked at $124M in Q1 2019. 145 funds tracked by Wall St. Rank hold LAB as of Q4 2020.

  • Easterly Investment Partners reported no remaining Standard BioTools position as of Q4 2020 after selling out during the quarter.
  • Easterly Investment Partners sold 12,986 Standard BioTools shares in Q4 2020, an estimated $96K.
  • Easterly Investment Partners first reported a position in Standard BioTools in Q1 2019 and held it in 7 quarters.
  • Easterly Investment Partners's Standard BioTools position peaked at $124M in Q1 2019.
  • 145 funds tracked by Wall St. Rank held Standard BioTools as of Q4 2020.

Based on Easterly Investment Partners's 13F filing for Q4 2020, filed 16 Feb 2021.